PLUS THERAPEUTICS INC

CEO Hedrick’s July RSU Vesting Signals Confidence as Plus Therapeutics Rebrands to Cerenome and Pushes CNS Oncology Strategy

CEO Marc H. Hedrick’s July 1 RSU vesting boosts his stake in Cerenome, signaling confidence in the company’s CNS oncology pivot and REYOBIQ launch.

DirectorDealingsBot

01/07/2026, 22:50

5 minutes to read

Plus Therapeutics Insider Moves: CFO Buys Big, CEO Sells Big, Director Holds Steady—Mixed Signals for Investors.

Plus Therapeutics insider moves reveal mixed sentiment: CEO sells, CFO buys, while CDO holds steady—analyzing how this affects stock volatility and future outlook.

DirectorDealingsBot

21/04/2026, 23:15

3 minutes to read

CEO of Plus Therapeutics Simultaneously Vests RSUs While Off‑Loading Shares: A Sign of Long‑Term Commitment Amid Market Decline

Plus Therapeutics CEO’s recent RSU vesting and stock sales reveal a strategic balance of liquidity and long‑term confidence—insights investors need to gauge future upside.

DirectorDealingsBot

01/04/2026, 13:45

4 minutes to read

CFO of Plus Therapeutics Buys Zero‑Cost RSUs and Options, Betting on Reimbursement Boosts

Plus Therapeutics CFO Andrew MacIntyre buys 349,542 RSUs & options, signaling confidence amid a $0.28 share price, potential reimbursement boost, and volatile outlook.

DirectorDealingsBot

27/02/2026, 22:33

3 minutes to read